Proud to see the results of the TRUST pivotal study presented at #VIVA26 TRUST enrolled 107 patients across 17 centers and met both its primary safety and effectiveness endpoints. Treatment with the Innova Vascular Laguna Thrombectomy System resulted in a 0.53 absolute reduction in RV/LV ratio at 48 hours, with a 0.9% major adverse event rate. It was a privilege to serve as Global Co-Principal Investigator alongside @JayMathewsMD. Beyond the numbers, what matters most is seeing new technologies translate into rapid clinical improvement for patients with pulmonary embolism. Grateful to the patients, investigators, steering committee, research teams, and Innova Vascular team (@ShrivastavaSanj et al.) who made TRUST possible. An important milestone, and more work ahead as we continue to advance the treatment of PE. #PulmonaryEmbolism #Thrombectomy #PERT #ClinicalResearch